Focus on lisdexamfetamine: A review of its use in child and adolescent psychiatry

Journal of the Canadian Academy of Child and Adolescent Psychiatry

Volumn 19, Issue 4, 2010, Pages 303-314

  Elbe, Dean ^a   MacBride, Angela ^b   Reddy, Dorothy ^a  

^a BC CHILDREN S HOSPITAL   (Canada)

^b ALBERTA CHILDREN'S HOSPITAL   (Canada)

Author keywords

ADHD; Amphetamine; Attention deficit; Hyperactivity; Lisdexamfetamine; Stimulants; Substance abuse

Indexed keywords

AMPHETAMINE; BIPHENTIN; DEXAMPHETAMINE; LISDEXAMFETAMINE; METHYLPHENIDATE; OMEPRAZOLE; PLACEBO; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ALOPECIA; ANOREXIA; ANXIETY; ATTENTION DEFICIT DISORDER; BLOOD PRESSURE; CHILD PSYCHIATRY; CLINICAL TRIAL; COUGHING; DECREASED APPETITE; DIZZINESS; DRUG ABSORPTION; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG COST; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG FORMULATION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG RELEASE; DRUG SAFETY; DRUG WITHDRAWAL; DYSURIA; EOSINOPHILIC HEPATITIS; FATIGUE; HEART PALPITATION; HEPATITIS; HUMAN; HYDROLYSIS; INFLUENZA; INSOMNIA; IRRITABILITY; MENTAL INSTABILITY; NAUSEA; NOSE CONGESTION; PSYCHOMOTOR DISORDER; PULSE RATE; REVIEW; RHINOPHARYNGITIS; SIDE EFFECT; STOMACH PH; TACHYCARDIA; UPPER ABDOMINAL PAIN; UPPER RESPIRATORY TRACT INFECTION; VASOSPASM; VOMITING; WEIGHT REDUCTION; XEROSTOMIA;

EID: 78049488098     PISSN: 17198429     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (36)

1. American Psychiatric Association (2000). Diagnostic and statistical manual of mental disorders (Revised 4th ed.). Washington, DC: Author.
2. Barrett, S. P., Darredeau, C., Bordy, L. E., & Pihl, R. O. (2005) Characteristics of methylphenidate misuse in a university student sample. Canadian Journal of Psychiatry 2005, 50(8), 457-461.
3. Biederman, J., Krishnan, S., Zhang, Y., McGough, J. J., & Findling, R. L. (2007a). Efficacy and Tolerability of Lisdexamfetamine Dimesylate (NRP-104) in Children with Attention-Deficit/Hyperactivity Disorder: A Phase III, Multicenter, Randomized, Double-Blind, Forced-Dose, Parallel-Group Study. Clinical Therapeutics, 29(3), 450-463.
4. Biederman, J., Boellner, S. W., Childress, A., Lopez, F. A., Krishnan, S., & Zhang, Y. (2007b). Lisdexamfetamine Dimesylate and Mixed Amphetamine Salts Extended-Release in Children with ADHD: A Double-Blind, Placebo-Controlled, Crossover Analog Classroom Study. Biological Psychiatry 2007, 62(9), 970-976.
5. Boellner, S. W., Stark, J. G., Krishnan, S., & Zhang, Y. (2010) Pharmacokinetics of Lisdexamfetamine Dimesylate and Its Active Metabolite, d-Amphetamine, With Increasing Oral Doses of Lisdexamfetamine Dimesylate in Children With Attention-Deficit/Hyperactivity Disorder: A Single-Dose, Randomized, Open-Label, Crossover Study. Clinical Therapeutics 2010, 32(2), 252-264.
6. Brahm, N. C., & Hamilton, D. R. (2009). Alopecia Following Initiation of Lisdexamfetamine in a Pediatric Patient. Primary Care Companion Journal of Clinical Psychiatry, 11(6), 365.
7. Brown, R. T., Freeman, W. S., Perrin, J. M., Stein, M. T., Amler, R. W., Feldman, H. M. et al. (2001). Prevalence and Assessment of Attention-Deficit/Hyperactivity Disorder in Primary Care Settings. Pediatrics, 107(3), e43.
8. CADDRA (Canadian ADHD Resource Alliance) (2008). Canadian ADHD Practice Guidelines. Retrieved July 14, 2010 from http://www.caddra.ca/cms4/index.php?option=com_content&view=articlea mp;&id=26&Itemid=70&lang=en
9. Centre for Evidence Based Medicine (2009). Levels of evidence. Retrieved July 7, 2009, from http://www.cebm.net/index.aspx?o=1025
10. Childress, A. C., Findling, R. L., Cutler, A. J., Gasior, M., Hamdani, M., Ferreira-Cornwell, C. et al. (2010). Efficacy and Safety of Lisdexamfetamine Dimesylate (LDX) in Adolescents With Attention-Deficit/Hyperactivity Disorder (ADHD). Retrieved July 12, 2010 from http://clinicaltrials.gov/ct2/show/NCT00735371.
11. Department of Health and Human Services, Centre for Disease Control and Prevention (2010). Youth Risk Behavior Surveillance-United States 2009. Morbidity & Mortality Weekly Report, 59(SS-5), 1-142.
12. DRUGDEX® Evaluations (Version 5.1) [Intranet]. Dextroamphetamine. Greenwood Village, CO: Thomson Reuters (Healthcare) Inc.
13. Easton, N., Steward, C., Marshall, F., Fone, K., & Marsden, C. (2007). Effects of amphetamine isomers, methylphenidate and atomoxetine on synaptosomal and synaptic vesicle accumulation and release of dopamine and noradrenaline in vitro in the rat brain. Neuropharmacology, 52(2), 405-414.
14. Ermer, J., Homolka, R., Martin, P., Buckwalter, M., Purkayastha, J., & Roesch, B. (2010). Lisdexamfetamine Dimesylate: Linear Dose-Proportionality, Low Intersubject and Intrasubject Variability, and Safety in an Open-Label Single-Dose Pharmacokinetic Study in Healthy Adult Volunteers. Journal of Clinical Pharmacology, Epub ahead of print, retrieved July 19, 2010 from http://jcp.sagepub.com.offcampus.lib.washington.edu/cgi/rapidpdf/0091270 009357346v1.pdf
15. Ermer, J., Dennis, K., Haffey, M, Doll, W. J., Sandefer, E. P., & Buckwalter, M. et al. (2009). Pharmacokinetics of intranasal versus oral administration of lisdexamfetamine dimesylate in healthy adults. Poster presentation at American Psychiatric Association 162nd annual meeting, May 16-21, 2009; San Francisco, CA.
16. Faraone, S. V., Spencer, T. J., Kollins, S. H., & Glatt, S. J. (2010). Effects of Lisdexamfetamine Dimesylate Treatment for ADHD on Growth. Journal of the American Academy of Child & Adolescent Psychiatry, 49(1), 24-32.
17. Findling, R. L., Ginsberg, L. D., Jain, R., & Gao, J. (2009). Effectiveness, Safety, and Tolerability of Lisdexamfetamine Dimesylate in Children With Attention-Deficit/Hyperactivity Disorder: An Open-Label, Dose-Optimization Study. Journal of Child and Adolescent Psychopharmacology, 19(6), 649-662.
18. Findling, R. L., Childress, A. C., Krishnan, S., & McGough, J. J. (2008). Long-Term Effectiveness and Safety of Lisdexamfetamine Dimesylate in school-aged children with Attention Deficit/Hyperactivity Disorder. CNS Spectrum, 13(7), 614-620.
19. Giblin, J. M., & Strobel, A. L. (2010) Effect of Lisdexamfetamine Dimesylate on Sleep in Children with ADHD. Journal of Attention Disorders. Epub ahead of print.
20. Goodman D., Scheckner, B., Dirks, B., Babcock, T., Adeyi, B., Lasser, R. et al. (2010). Safety profile of Lisdexamfetamine Dimesylate in Short-Term Clinical Trials in Children, Adolescents and Adults with Attention-Deficit/Hyperactivity Disorder. Poster presentation at American Psychiatric Association 163rd annual meeting, May 22-25, 2010; New Orleans, LA.
21. Haffey, M. B., Buckwalter, M., Zhang, P., Homolka, R., Martin, P., Lasseter, K. C. et al. (2009). Effects of omeprazole on the pharmacokinetic profiles of lisdexamfetamine dimesylate and mixed amphetamine salts extended release in adults. Postgraduate Medicine, 121(5), 11-19.
22. Hood, B., & Nowicki, M. J. (2010). Eosinophilic Hepatitis in an Adolescent During Lisdexamfetamine Dimesylate Treatment for ADHD. Pediatrics, 125, e1510-e1513.
23. Jasinski, D. R., & Krishnan, S. (2009a) Human pharmacology of intravenous lisdexamfetamine dimesylate: abuse liability in adult stimulant abusers. Journal of Psychopharmacology, 23(4), 410-418.
24. Jasinski, D. R., & Krishnan, S. (2009b). Abuse liability and safety of oral lisdexamfetamine dimesylate in individuals with a history of stimulant abuse. Journal of Psychopharmacology, 23(4), 419-427.
25. Jasinksi, D. R., & Krishnan, S. (2006). Pharmacokinetics of Oral Lisdexamfetamine Dimesylate (LDX; NRP104) vs d-Amphetamine in Healthy Adults with a History of Stimulant Abuse. Poster presentation at the 2006 U. S. Psychiatric & Mental Health Congress, November 17, 2006; New Orleans, LA.
26. Krishnan, S. M., & Stark, J. G. (2008). Multiple daily-dose pharmacokinetics of lisdexamfetamine dimesylate in healthy adult volunteers. Current Medical Research and Opinion, 24(1), 33-40.
27. Krishnan, S., & Zhang, Y. (2008). Relative Bioavailability of Lisdexamfetamine 70-mg Capsules in Fasted and Fed Healthy Adult Volunteers and in Solution: A Single-Dose, Crossover Pharmacokinetic Study. Journal of Clinical Pharmacology, 48(3), 293-302.
28. Krishnan, S., & Moncrief, S. (2007). An Evaluation of the Cytochrome p450 Inhibition Potential of Lisdexamfetamine in Human Liver Microsomes. Drug Metabolism and Disposition, 35(1), 180-184.
29. TM, Hudson, Ohio: Lexi-Comp, Inc.; 2010; July 14, 2010.
30. Lopez, F. A., Boellner, S. W., Childress, A., Krishnan, S., & Biederman, J. (2006). ADHD symptom improvement in children treated with lisdexamfetamine dimesylate (LDX). Presented at the 53rd annual meeting of the American Academy of Child and Adolescent Psychiatry, October 28, 2006; San Diego, CA.
31. Pennick, M. (2010). Absorption of lisdexamfetamine dimesylate and its enzymatic conversion to d-amphetamine. Neuropsychiatric Disease and Treatment, 6, 317-327.
32. Plizska, S. R., Crimson, M. L., Hughes, C. W., Conners, C. K., Emslie, G. J. Jensen, P. S. et al. (2006). The Texas Children's Medication Algorithm Project: Revision of the Algorithm for Pharmacotherapy of Attention-Deficit/Hyperactivity Disorder. Journal of the American Academy of Child and Adolescent Psychiatry, 45(6), 642-657.
33. Shire Canada, Inc. (2010). Vyvanse® Product Monograph. Saint-Laurént, QC: Shire Canada Inc.
34. Varughese, S., Rosen, S., Ertischek, M. D., Sembower, M. A., St. Jean, E., & Schnoll, S. H. (2010). Non-medical use surveillance and signal identification of lisdexamfetamine dimesylate, a pro-drug stimulant for the treatment of ADHD. Poster presentation at American Psychiatric Association 163rd annual meeting, May 22-27, 2010; New Orleans, LA.
35. Wigal, S. B., Kollins, S. H., Childress, A. C., & Squires, L. (2009). A 13-hour laboratory school study of lisdexamfetamine dimesylate in school-aged children with attention-deficit/hyperactivity disorder. Child and Adolescent Psychiatry and Mental Health, 3(1), 17.
36. Wilens, T. E., Adler, L. A., Adams, J., Sgambati, S., Rotrosen, J., Sawtelle, R. et al. (2008). Misuse and Diversion of Stimulants Prescribed for ADHD: A Systematic Review of the Literature. Journal of the American Academy of Child and Adolescent Psychiatry, 47(1), 21-31.